The large global CDMO market presents an attractive opportunity, with small and large companies looking for specialist technologies, expertise and quality to help develop their products.

Vectura is focused on delivering inhaled product development services to pharmaceutical and biotech customers globally. The company has a unique service offering with proven expertise and capabilities, validated formulation and device technologies, and a track record of helping partners bring products to market.

Our talented people

We have 450+ employees working internationally across five sites with extensive formulation, device, product development and regulatory expertise.


Our customers are developing a broad range of small and large molecules, using lung delivery to treat a wide range of diseases.

With a track record of innovation and our specialist technologies, Vectura can meet these needs, creating IP and value for customers, partners and shareholders.

Customer and Patient focus

We recognise our customers’ specific requirements and challenges in bringing new inhaled medicines to market. By understanding patients’ needs, we are able to develop innovative technologies that improve people’s lives.

Our shared culture

Our shared values foster a strong culture which is a definitive expression of “how we do things” at Vectura

Our intellectual property

We have a broad IP base covering our technologies and capabilities, managed by our experienced in-house team

Our strong partnerships

We have an active portfolio of partnerships with leading pharmaceutical and biotech companies which has delivered eleven products to market.


Optimising drug and excipients to deliver required clinical profile


Range of devices to address differing drug delivery characteristics and patient needs


In-house expertise in support of the development process from early stage through to approval and launch

Leveraging our differentiated technology and expertise to provide product development services for our customers and drive value for Vectura’s shareholders.

Development revenues

Product supply


Our shareholders

Maintaining a strong balance sheet by ensuring focused investment and delivering for customers to target long term growth

Our customers, partners and patients

Leveraging our differentiated technologies and expertise to provide Vectura’s expertise to customers and partners, helping them develop medicines to improve people’s lives.

Our people

Creating a dynamic and rewarding place to work with clear development opportunities

Our partners

Leveraging Vectura’s capabilities to support the scientific and operational development of new and inhaled generic products which deliver returns for our partners

Our environment and local communities

Offering good quality employment opportunities and a long-term positive impact on our environment and communities